Niklas Schäfer

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Ulrich Herrlinger, Niklas Schäfer, Astrid Weyerbrock et al. · Journal of Clinical Oncology · 2016 · 197 citations

Medicine, Oncology, Pharmacotherapy +15

<i>DJ-1 (PARK7)</i> mutations are less frequent than <i>Parkin (PARK2)</i> mutations in early-onset Parkinson disease

Katja Hedrich, Ana Djarmati, Niklas Schäfer et al. · Neurology · 2004 · 181 citations

Life Sciences, Genetics, Molecular Genetics +17

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

Sied Kebir, Rolf Fimmers, Norbert Galldiks et al. · Clinical Cancer Research · 2015 · 126 citations

Medicine, Nuclear Medicine, Oncology +17

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection

Pawel Kermer, Christoph Eschenfelder, Hans‐Christoph Diener et al. · International Journal of Stroke · 2017 · 92 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17